Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

被引：5
|
作者：
Palmer, Daniel H.
Ma, Yuk Ting
Peck-Radosavljevic, Markus
Ross, Paul J.
Graham, Janet Shirley
Fartoux, Laetitia
Deptala, Andrzej
Wenz, Arne
Hocke, Julia
Loembe, Arsene-Bienvenu
Meyer, Tim
机构：
[1] Univ Liverpool, Canc Res UK Ctr, Liverpool L69 3BX, Merseyside, England
[2] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England
[3] Univ Hosp Birmingham NHS Fdn Trust, Ctr Canc, Birmingham, W Midlands, England
[4] Med Univ Wien, Dept Gastroenterol & Hepatol, Vienna, Austria
[5] Kings Coll Hosp NHS Fdn Trust, London, England
[6] Univ Glasgow, Beatson Labs, Glasgow, Lanark, Scotland
[7] Hop St Antoine, F-75571 Paris, France
[8] Minist Interior, Cent Clin Hosp, Dept Hematol & Oncol, Warsaw, Poland
[9] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[10] Boehringer Ingelheim BV, Alkmaar, Netherlands
[11] UCL Canc Inst, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
238
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) vs sorafenib in patients with advanced HCC
    Yau, Thomas
    Kwok, Gin Wai
    Tang, Vikki
    Leung, Roland
    Lee, Ann-Shing
    Law, Ada
    Chiu, Joanne
    Li, Bryan
    Cheung, Tan-To
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 92 - 92
  • [32] Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
    Ikeda, M.
    Shimizu, S.
    Sato, T.
    Morimoto, M.
    Kojima, Y.
    Inaba, Y.
    Hagihara, A.
    Kudo, M.
    Nakamori, S.
    Kaneko, S.
    Sugimoto, R.
    Tahara, T.
    Ohmura, T.
    Yasui, K.
    Sato, K.
    Ishii, H.
    Furuse, J.
    Okusaka, T.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (11) : 2090 - 2096
  • [33] Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).
    Ciuleanu, Tudor-Eliade
    Bazin, Igor
    Lungulescu, Dan
    Miron, Lucian
    Bondarenko, Igor
    Deptala, Andrzej
    Rodriguez-Torres, Maribel
    Giantonio, Bruce J.
    Sun, Weijing
    Fox, Norma Lynn
    Aktan, Gursel
    Wissel, Paul Stephen
    Egger, Jacki
    Ding, Meichun
    Kalyani, Rubana
    Gribbin, Matthew Joseph
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Phase II trial of tepotinib vs sorafenib for treatment-naive advanced hepatocellular carcinoma (HCC) in Asian patients
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [35] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials
    Llovet, J.
    Cheng, A.
    Qin, S.
    Shan, M.
    Nadel, A.
    Burock, K.
    Forner, A.
    Zou, J.
    Bruix, J.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 367 - 367
  • [36] A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta L.
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
    Marta, Guilherme Nader
    da Fonseca, Leonardo G.
    Braghiroli, Maria Ignez
    Moura, Fernando
    Hoff, Paulo M.
    Sabbaga, Jorge
    [J]. CLINICS, 2021, 76 : 1 - 6
  • [38] SAFETY AND EFFICACY OF SORAFENIB FOR ADVANCED HEPATOCELLULAR CARCINOMA
    Sacco, P. C.
    De Sanctis, R.
    Quadrini, S.
    Gori, B.
    Del, Signore E.
    Stumbo, L.
    Tedeschi, M.
    Falbo, P. T.
    Fulvi, A.
    Grassi, P.
    Sollami, R.
    Basile, M. L.
    Di Seri, M.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [39] Efficacy and safety of a phase II study of sorafenib plus gemcitabine in advanced hepatocellular carcinoma.
    Srimuninnimit, V.
    Sriuranpong, V.
    Suwanvecho, S.
    Soparattanapaisarn, N.
    Ithimakin, S.
    Akewanlop, C.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Kiatikajornthada, N.
    Suwanrusme, H.
    Chaiyarat, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
    El Dika, Imane
    Capanu, Marinela
    Chou, Joanne F.
    Harding, James J.
    Ly, Michele
    Hrabovsky, Anna D.
    Do, Richard K. G.
    Shia, Jinru
    Millang, Brittanie
    Ma, Jennifer
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    [J]. CANCER MEDICINE, 2020, 9 (20): : 7453 - 7459
12345